ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,431.60
-0.04%
US Tech 100
19,168.00
0.52%
다우존스 지수
38,589.16
-0.15%
Bitcoin
66,452.57
-0.28%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Alkermes PLC (ALKS)

  7. Alkermes PLC (ALKS) 뉴스

ALKS

Alkermes (ALKS)

Alkermes PLC
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:ALKS
일자시간출처헤드라인심볼기업
2024/06/1109:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
2024/06/1109:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
2024/06/0506:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
2024/06/0506:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
2024/06/0505:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
2024/06/0505:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
2024/06/0505:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
2024/06/0505:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
2024/06/0320:00PR Newswire (US)Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024NASDAQ:ALKSAlkermes PLC
2024/06/0105:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALKSAlkermes PLC
2024/05/3005:00PR Newswire (US)Alkermes to Participate in Two Upcoming Investor ConferencesNASDAQ:ALKSAlkermes PLC
2024/05/3005:00PR Newswire (US)Alkermes to Participate in Two Upcoming Investor ConferencesNASDAQ:ALKSAlkermes PLC
2024/05/2820:00PR Newswire (US)Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024NASDAQ:ALKSAlkermes PLC
2024/05/2820:00PR Newswire (US)Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024NASDAQ:ALKSAlkermes PLC
2024/05/1505:30Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ALKSAlkermes PLC
2024/05/1420:00PR Newswire (US)Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific ConferencesNASDAQ:ALKSAlkermes PLC
2024/05/1420:00PR Newswire (US)Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific ConferencesNASDAQ:ALKSAlkermes PLC
2024/05/0220:00PR Newswire (US)Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo NordiskNASDAQ:ALKSAlkermes PLC
2024/05/0120:00PR Newswire (US)Alkermes plc Reports First Quarter 2024 Financial ResultsNASDAQ:ALKSAlkermes PLC
2024/04/2420:00PR Newswire (US)Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1NASDAQ:ALKSAlkermes PLC
2024/04/1805:00PR Newswire (US)Alkermes to Report First Quarter Financial Results on May 1, 2024NASDAQ:ALKSAlkermes PLC
2024/04/1805:00PR Newswire (US)Alkermes to Report First Quarter Financial Results on May 1, 2024NASDAQ:ALKSAlkermes PLC
2024/04/0920:00PR Newswire (US)Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic HypersomniaNASDAQ:ALKSAlkermes PLC
2024/04/0920:00PR Newswire (US)Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic HypersomniaNASDAQ:ALKSAlkermes PLC
2024/04/0820:00PR Newswire (US)Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research SocietyNASDAQ:ALKSAlkermes PLC
2024/03/0721:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALKSAlkermes PLC
2024/03/0721:00PR Newswire (US)Alkermes Announces Appointment of Nancy S. Lurker to Board of DirectorsNASDAQ:ALKSAlkermes PLC
2024/02/2806:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
2024/02/2806:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
2024/02/2806:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
 검색 관련기사 보기:NASDAQ:ALKS

최근 히스토리

SPI
SP500
S&P 500
NASDAQ
AMZN
Amazon.com
NYSE
NKE
Nike
NASDAQ
TSLA
Tesla
NYSE
MRK
Merck
CCOM
US30
US 30
COIN
ETHUSD
Ethereum
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
KO
Coca Cola
NASDAQ
NVDA
NVIDIA
USI
USTECH100
US Tech 100
NASDAQ
AAPL
Apple
CCOM
SILVER
SILVER
NYSE
JPM
JP Morgan Chase
CCOM
US500
US 500
USOTC
RHHBY
Roche (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유